HALO•November 17, 2026 at 4:31 PM UTCPharmaceuticals, Biotechnology & Life Sciences

HALO's 40% Rally Tests Valuation as ENHANZE Strength Meets Looming Risks

Read source article

What happened

Halozyme's stock has surged over 40% in six months, driven by robust ENHANZE royalties from blockbuster subcutaneous biologics and management's raised revenue guidance, but the master report flags that the market may be getting ahead of fundamentals. The current price trades roughly 33% above a DCF estimate of $49.46, despite strong near-term cash flows and interest coverage. Core risks remain ahead: ENHANZE's composition-of-matter patents begin expiring in 2027, partner concentration is high (two customers were 58% of 2024 revenue), and the company carries ~2.1x net debt/EBITDA with large 2027-2028 maturities. Aggressive M&A (Antares, Elektrofi, potential Evotec) adds execution and integration uncertainty not yet reflected in the rally. The article's bullish tone ignores these structural challenges, leaving the stock vulnerable if growth expectations reset.

Implication

Investors should resist chasing the rally, as the stock trades above intrinsic value and faces known headwinds like the 2027 ENHANZE patent cliff and debt maturities. Monitoring ENHANZE litigation outcomes and partner royalty trends will be critical for assessing post-2027 cash flows. The company's leveraged balance sheet means refinancing of 2027-2028 debt and M&A integration will heavily influence downside protection. A pullback toward the ~$50 DCF anchor would improve the risk/reward profile, while further multiple expansion without a commensurate rise in free cash flow increases vulnerability. Maintain a patient stance, waiting for either a more attractive entry point or clear evidence that the growth story extends beyond the current IP horizon.

Thesis delta

The six-month rally reinforces ENHANZE's near-term execution, but the core thesis risks remain unresolved: the 2027 IP expiry, high partner concentration, and debt-funded M&A all still weigh on the long-term outlook. The stock is now trading roughly 33% above our DCF estimate, which has further compressed the margin of safety rather than providing a buying opportunity. Therefore, the prior WAIT judgment is affirmed, and no upgrade is warranted based solely on price momentum or raised guidance.

Confidence

High